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Summary 
Matriptase is a type-II transmembrane serine protease involved in epithelial homeostasis 
in both health and disease, and is implicated in the development and progression of a variety 
of cancers. Matriptase mediates its biological effects both via as yet undefined substrates and 
pathways, and also by proteolytic cleavage of a variety of well-defined protein substrates, 
several of which it shares with the closely-related protease hepsin. Development of targeted 
therapeutic strategies will require discrimination between these proteases. Here we have 
investigated cyclic microproteins of the squash Momordica cochinchinensis trypsin-inhibitor 
family (generated by total chemical synthesis) and found MCoTI-II to be a high-affinity (Ki 9 
nM) and highly selective (> 1000-fold) inhibitor of matriptase. MCoTI-II efficiently inhibited 
the proteolytic activati n of pro-hepatocyte growth factor (HGF) by matriptase but not by 
hepsin, in both purified and cell-based systems, and inhibited HGF-dependent cell scattering. 
MCoTI-II also selectively inhibited the invasion of matriptase-expressing prostate cancer 
cells. Using a model of epithelial cell tight junction assembly, we also found that MCoTI-II 
could effectively inhibit the re-establishment of tight junctions and epithelial barrier function 
in MDCK-I cells after disruption, consistent with the role of matriptase in regulating epithelial 
integrity. Surprisingly, MCoTI-II was unable to inhibit matriptase-dependent proteolytic 
activation of prostasin, a GPI-anchored serine protease also implicated in epithelial 
homeostasis. These observations suggest that the unusually high selectivity afforded by 
MCoTI-II and its biological effectiveness might represent a useful starting point for the 
development of therapeutic inhibitors, and further highlight the role of matriptase in epithelial 
maintenance.  
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Introduction 
Proteolytic enzymes play key regulatory roles in a wide variety of physiological and 
pathological process, ranging from fertility and development to cancer invasion and 
metastasis. The majority of these enzymes are soluble, extracellular proteins. However, a 
limited number are associated with the cell surface, restricting their activity to the pericellular 
environment and enabling them to affect cell function. This association can occur either 
through binding to membrane receptors or their expression as integral membrane proteins (1, 
2). The latter includes matriptase, which is a member of the type-II transmembrane serine 
protease (TTSP) family (2, 3).  
Matriptase is overexpressed in a wide range of human epithelial tumours, and often 
correlated with clinical outcome (4, 5). Experimental evidence suggests that the proteolytic 
activity of matriptase may be causally associated with tumour development, as a low level of 
orthotopic expression of matriptase in mice leads to spontaneous tumours and increased 
carcinogen susceptibility (6, 7). Matriptase also has essential physiological functions in 
regulating the integrity of epithelial tissues. Mice with targeted deletion of matriptase have a 
severe epidermal barrier defect leading to neonatal mortality (8), and a mutation in matriptase 
that leads to reduced protease activity is associated with the human syndrome autosomal 
recessive ichthyosis with hypotrichosis (9). Conditional deletion of matriptase in mice 
demonstrates that it has a more wide-ranging postnatal effect on epithelial tissues leading to 
severe organ dysfunction (10), and intestinal barrier competence is lost in matriptase 
hypomorphic mice (11). 
Matriptase, in common with the other TTSPs, has trypsin-like substrate specificity, 
hydrolysing the peptide bond C-terminal of the Lys or Arg side-chains that occupy the S1 
primary substrate specificity pocket. The extended peptide substrate specificity of matriptase 
has been determined (12, 13) and several protein substrates have been indentified in vitro. 
These include three proteins that can be considered to be serine protease zymogens, 
suggesting that matriptase is involved in zymogen activation cascades. These are the soluble 
serine protease uPA (12, 14, 15), the GPI-anchored serine protease prostasin (16) and 
hepatocyte growth factor (HGF) (13, 14), a plasminogen-related growth factor also known as 
scatter factor. In addition to activating these substrates by limited proteolysis in purified 
systems, matriptase has also been shown to catalyse these reactions with high efficiency on 
the cell-surface. Endogenous matriptase on the surface of leukocytes has been demonstrated 
to proteolytically activate pro-uPA bound to its GPI-anchored cellular receptor uPAR and 
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thereby facilitate pericellular plasmin generation (15), and endogenous matriptase mediates 
pro-HGF-dependent epithelial cell scattering (13). The proteolytic activation of each of these 
zymogens may potentially be involved in the pro-carcinogenic and other biological activities 
of matriptase (2, 7, 17). Interestingly, another TTSP, hepsin, appears to have protein substrate 
specificity that overlaps to a large extent with that of matriptase,. Hepsin has been shown to 
activate pro-uPA, pro-HGF and pro-prostasin (13, 18-20), despite having a dissimilar peptide 
substrate specificity to that of matriptase (13). 
Proteolytic enzymes as a class are considered to be a major part of the druggable genome 
(21, 22), and inhibition of matriptase activity may therefore be an attractive target for 
therapeutic intervention in cancer. Although effective inhibition of protease activity is easily 
accomplished using synthetic small molecule inhibitors, selectivity of inhibition is much more 
difficult to achieve, particularly between closely related proteases. The well-publicised failure 
of clinical trials of matrix metalloprotease inhibitors in cancer is believed to be largely a 
consequence of such a lack of selectivity, i.e. inhibition of metalloproteases in addition to the 
target, with potentially differing biological activities (22, 23). Therefore, the ability to 
discriminate between matriptase and hepsin, with their overlapping substrate specificities, 
must be considered to be an important goal in the development of an effective inhibitory 
strategy targeted at matriptase activity.  
To achieve this, and to overcome the possible limitations of small molecule inhibitors, we 
have investigated the unique class of macrocyclic cystine-knot microproteins known as 
cyclotides. These plant-derived cyclic proteins include Momordica cochinchinensis trypsin 
inhibitor-II (MCoTI-II), a 34-residue cyclotide originally isolated from the Vietnamese 
squash. These cyclotides have an exceptionally rigid structure, are highly resistant to thermal 
and enzymatic degradation, and have a high stability in vivo (24). We have developed an 
efficient strategy for the total chemical synthesis of MCoTI-II, which can be used as a 
scaffold for the introduction of sequence variations aimed at modulating the affinity and 
specificity of inhibition (25-27). In the present study we have found that it is a highly specific 
and selective inhibitor of the biochemical and biological activities of matriptase, and that it 
has no detectable effect on the activity of hepsin. MCoTI-II effectively inhibits the activity of 
matriptase against both peptide and protein substrates, and potently inhibits the activity of 
matriptase in several complex cellular systems that reflect its in vivo functions. The inhibitory 
characteristics of MCoTI-II, and its wide-ranging biological effects, suggest that it may be a 
potential candidate for the development of matriptase-targeted therapeutic strategies.  
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Materials and methods 
Proteins and reagents  
MCoTI-II, MCoTI-II[K10R], MCoTI, MCoEeT-I and MCoEeT-I[K10R] were produced by 
total chemical synthesis as previously described (25, 27). Soluble matriptase, soluble hepsin 
and pro-HGF (with a C-terminal V5-His tag) were all expressed and purified as previously 
described (13). Recombinant human kallikrein-2 (KLK2) and kallikrein-3 (KLK3) were 
purchased from R&D Systems (Abingdon, UK). The fluorogenic peptide substrates H-D-Val-
Leu-Lys-7-amino-4-methylcoumarin and H-Glu-Gly-Arg-7-amino-4-methylcoumarin were 
purchased from MP Biomedicals (Cambridge, UK). Mouse anti-V5 antibody was from 
Invitrogen (Paisley, UK), mouse anti-prostasin from BD Biosciences (Oxford, UK), rabbit 
anti-claudin-1 and mouse anti-ZO-1 from Sigma-Aldrich (Poole, UK) and Alexa 488-labelled 
goat anti-mouse and Alexa 647-labelled goat anti-rabbit IgG from Abcam (Cambridge, UK). 
Cell culture 
Madine-Darby canine kidney cells (MDCK-I, MDCK-II) and HEK293 cells were routinely 
maintained in DMEM supplemented with 10% FCS and 2 mM L-glutamine. PC-3 cells were 
maintained in RPMI medium containing 10% FCS and 2 mM L-glutamine. All cell culture 
reagents were from Invitrogen. 
Determination of Ki values for protease inhibition 
Purified soluble matriptase (5 nM) or hepsin (2 nM) was incubated with varying 
concentrations of H-D-Val-Leu-Lys-7-amino-4-methylcoumarin (0 – 0.5 mM) in 50 mM Tris-
HCl pH 7.6, 100 mM NaCl, 0.01% Tween 80. Varying concentrations of MCoTI-II or its 
derivatives were included in these incubations and substrate hydrolysis monitored 
continuously using a Spectramax Gemini fluorescence microplate reader (Molecular Devices, 
Berkshire, UK) using excitation and emission wavelengths of 360 nm and 440 nm, 
respectively. Vmax and Km values were determined from initial reaction rates at each substrate 
and inhibitor concentration and Ki values subsequently calculated from plots of Km/Vmax vs. 
[inhibitor], as previously described (13). For each Ki determination, at least four substrate and 
four inhibitor concentrations were used, with each analysis performed in triplicate. Ki values 
for other proteases were determined as previously described (27). The Ki was also determined 
for the inhibition of pro-uPA activation using a range of pro-uPA concentrations (0.05 - 1 
µM). Ki was calculated from plots of Km/Vmax vs. [inhibitor], as previously described (13). 
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Inhibition of pro-HGF and pro-uPA activation 
Purified pro-HGF or pro-uPA (both expressed in Drosophila S2 cells with a C-terminal V5-
epitope tag) was incubated with either soluble matriptase or soluble hepsin in 50 mM Tris-
HCl pH 7.6, 100 mM NaCl, 0.01% Tween 80, in the presence of varying concentrations of 
MCoTI-II. Aliquots of equal volume were taken from each reaction at timed intervals and the 
reaction terminated by addition of SDS-PAGE sample buffer containing dithiothreitol. 
Samples were analysed by SDS-PAGE and western blotting using anti-V5 primary antibody, 
as previously described (13). 
Inhibition of cell-mediated pro-HGF activation  
MDCK-II or PC-3 cells were seeded at a density of 1x104
 
cells per well in 96 well plates and 
allowed to adhere overnight. The cells were washed in serum-free medium prior to incubation 
with purified V5-tagged pro-HGF in the presence of MCoTI-II (100 nM or 500 nM). Medium 
was collected at timed intervals, the reaction terminated by addition of SDS-PAGE sample 
buffer containing dithiothreitol, and the samples analysed for pro-HGF activation by SDS-
PAGE and western blotting for the V5 epitope. 
Cell scatter assay 
The biological activity of HGF was determined by its effect on the scattering of MDCK-II 
cells as previously described (13). Cells were seeded at a density of 1 x 103 cells per well and 
left to adhere overnight. Pro- or active HGF (10 ng/ml) was added in the presence of varying 
concentrations of MCoTI-II (0 - 500 nM) in serum-free medium. After 30 hours the cells were 
washed twice with PBS and fixed with ice-cold methanol for 5 minutes, followed by a further 
PBS wash. Images were taken using a Zeiss CCD inverted microscope using x10 
magnification. Treatments were performed in duplicate in three independent experiments. 
Matrigel invasion assay 
Precoated matrigel invasion chambers (BD Biosciences) were seeded with PC-3 cells at a 
density of 1 x 105
 
per in well in 200 µl serum-free medium. The lower chamber contained 2% 
FCS as a chemoattractant and the cells were allowed to invade the matrigel for 24 hours in the 
presence of varying concentrations of MCoTI-II (0 – 500 nM). Non-invading cells and 
matrigel were removed and the cells on the underside of the membrane fixed with methanol, 
stained with haematoxylin-eosin and mounted in hydromount (National Diagnostics, Hull, 
UK). Invaded cells were counted using an inverted microscope, using three randomly chosen 
fields for each membrane. Each experimental condition was performed in duplicate and the 
experiment carried out on three separate occasions. Data were analysed using Student’s t-test.  
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Transepithelial electrical resistance (TEER) measurements  
MDCK-I cells (25,000/well) were seeded in triplicate into 6.5 mm Transwell chambers with 
0.4 µm pores (Costar, Corning Life Sciences, MA, USA). The transepithelial ion permeability 
of was determined every 24 hours by measuring electric resistance across the monolayer using 
the EVOM Epithelial Voltohmmeter (World Precision Instruments, Saratosa, FL, USA). The 
medium in both internal and external compartments of each Transwell was changed every 2 
days, and contained varying concentrations of MCoTI-II. In Ca2+-switch experiments, cell 
monolayers with a stable level of TEER were incubated with Spinner’s Ca++-free medium for 
16 hours, followed by restoration of normal culture conditions.  
Immunofluorescence microscopy 
MDCK-I cells were gr wn on 6.5 mm polyester Transwell inserts with 0.4 µm pores (Costar) 
for 5 days. Cells were fixed in methanol at -20° C, washed 3 times in PBS, 3 times with 1% 
goat serum/PBS and incubated with 10% goat serum/PBS at room temperature. Cells were 
incubated with primary antibodies against claudin-1 (1:100) and ZO-1 (1:50), washed and 
incubated with Alexa-labelled secondary antibodies (1:1000). Cells were mounted in Pro-
Long Gold antifade reagent (Invitrogen) and images obtained using x63 magnification on a 
Zeiss Axiovert 200M equipped with a Zeiss AxioCam and Axiovision software.  
qRT-PCR  
Matriptase expression in MDCK-I and MDCK-II cells was determined by qRT-PCR using 
SYBR-Green chemistry (Life Technologies, Warrington, UK). First-strand cDNA was 
synthesised from total RNA using random hexamer priming. qRT-PCR was performed on an 
ABI 7700 (Life Technologies) using primers for canine matriptase; forward 5’-
ACAGAACCAGCAGTGTGACG-3’, reverse 5’-ACTCTTCCTAACGCTGACAC-3’. Data 
are shown relative to the expression of 18S rRNA, which was used as an endogenous control. 
Prostasin activation 
HEK293 cells were transfected with full-length human prostasin cDNA in pIRES2-EGFP 
(16) and full-length matriptase cDNA in pcDNA3.1 (13) either alone or in combination using 
Fugene transfection reagent under serum free conditions according to manufacturer’s 
guidelines (Promega, Southampton, UK). Cells were incubated for 24 hours, washed and 
placed in serum-containing medium for a further 24 hours. Cells were lysed, samples run on 
SDS-PAGE under reducing conditions and western blot performed with an anti-prostasin 
antibody. To determine the effect of matriptase inhibition, MCoTI-II was added at 6 hours 
post-transfection, and added again at 24 hours when the medium was changed.
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Results 
Selective inhibition of matriptase by MCoTI-II 
The ability of the squash trypsin inhibitor MCoTI-II and various derivatives, with sequence 
variations around the reactive centre residue, to inhibit matriptase and hepsin was initially 
tested in solution using soluble forms of these proteases and a tripeptide fluorogenic peptide 
substrate. Analysis of Ki values revealed that MCoTI-II was the most effective inhibitor of 
matriptase activity, with a Ki value of 9 nM (Table 1). Replacement of the P1 residue (Lys-
10) of MCoTI-II with Arg resulted in an 18-fold increase in Ki value, consistent with the 
slight preference for Lys over Arg at P1 displayed by matriptase against peptide substrates 
(13). MCoEeTI, a hybrid with the related cystine-knot trypsin inhibitor from Ecballium 
elaterium (EETI-II), displayed a 60-fold increased Ki value for matriptase, which in this case 
was slightly improved by Lys to Arg substitution at P1. The natural variant MCoTI-I, 
differing from MCoTI-II by two residues in a loop distal to the reactive centre loop, was also 
a less effective inhibitor of matriptase. 
In sharp contrast, none of the inhibitors had detectable activity against the closely related 
type-II transmembrane serine protease, hepsin, with at least a 1000-fold difference in Ki value 
in the case of MCoTI-II. Notably, the two variants with Arg at P1, matching the very strong 
P1 preference of hepsin (13), also had no detectable inhibitory activity against hepsin. 
A range of other serine proteases, mainly with trypsin-like activities, were also tested. Of 
these, only trypsin itself and β-tryptase were inhibited to any quantifiable extent.  
 
Specific inhibition of matriptase-catalysed activation of pro-HGF by MCoTI-II 
Having established that MCoTI-II is an effective and selective inhibitor of the activity of 
matriptase against a small peptide substrate, we aimed to determine whether MCoTI-II was 
also effective in inhibiting macromolecular substrate hydrolysis. Pro-HGF has been 
established as a key substrate for matriptase in solution, at the cell-surface and in vivo (7, 13). 
Therefore, the effect of MCoTI-II on the activation of purified pro-HGF by soluble matriptase 
was investigated, using western blotting for detection. MCoTI-II was observed to completely 
inhibit the activation of pro-HGF at increasing concentrations (Fig. 1A, left panel). Inhibition 
was detectable at concentrations above 10 nM, and was essentially complete at concentrations 
above 100 nM consistent with the determined Ki value of 9 nM. Also consistent with our 
initial observations, activation of pro-HGF by soluble hepsin was not inhibited by MCoTI-II 
at concentrations up to 500 nM (Fig. 1A, right panel).  
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The proteolytic activation of pro-uPA by matriptase and hepsin was also affected by 
MCoTI-II in a manner consistent with these observations (Fig. 1B). The inhibition of 
matriptase-catalysed pro-uPA activation by MCoTI-II was also analysed by enzyme kinetics 
(Fig. 1C, left panel). From these, and similar data at other concentrations of pro-uPA, a Ki 
value of 15 nM was determined, in close agreement with the Ki value determined directly by 
peptide substrate hydrolysis (Table 1). No inhibition of hepsin-catalysed pro-uPA activation 
was observed (Fig. 1C, right panel), consisitent with the high selectivity of MCoTI-II. 
 
Inhibition of the cellular activation of pro-HGF by MCoTI-II 
Having demonstrated the efficacy of MCoTII-II at inhibiting the proteolytic activity of 
matriptase in solution, its activity against endogenous, membrane-associated matriptase was 
investigated. We have previously demonstrated that pro-HGF is efficiently activated by the 
prostate cancer cell line PC-3, and that this activation can be abolished by matriptase-
targeting siRNA (13). Therefore, the ability of MCoTI-II to inhibit the cellular activation of 
pro-HGF was determined using this system. The data in Fig. 2 show that using 100 nM 
MCoTI-II, partial and variable inhibition of pro-HGF activation was observed at two different 
time points, and that inhibition was essentially complete at 500 nM of the cyclotide inhibitor. 
These concentrations are less than 5-fold higher than those giving comparable inhibition in 
the purified system, and therefore it appears that endogenous, transmembrane matriptase is 
completely accessible to the macromolecular inhibitor MCoTI-II.  
The dog cell-line MDCK is a well-established model system used to study many aspects 
of epithelial biology, and may represent a useful model for the study of matriptase function. 
Therefore the ability of MCoTI-II to inhibit matriptase-dependent pro-HGF activation on 
these cells was also determined, employing the widely-used MDCK-II strain (28). The results 
were similar to those observed with PC-3 cells, with complete inhibition of pro-HGF 
activation between 100-500 nM MCoTI-II (Fig. 2). Therefore the potency of MCoTI-II is 
retained for the inhibition of dog matriptase, and MDCK cells can be used to further study the 
role of matriptase in epithelial cell function.  
 
Effect of inhibition of matriptase activity on HGF-induced cell scatter 
Binding of activated HGF to its singular cell-surface receptor c-Met causes a well-described 
dissolution of cell-cell junctions and scattering of MDCK-II cells, the initial stages of 
epithelial-mesenchymal transition. Pro-HGF cannot signal through c-Met, but cell scattering 
can be promoted by the pericellular proteolytic activation of pro-HGF (13). Therefore, the 
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ability of MCoTI-II to inhibit cell scattering in the presence of pro-HGF was determined. 
MDCK-II cells at low density grow as tightly packed colonies (Fig. 3A), which disperse upon 
treatment with either active HGF (Fig. 3B) or pro-HGF (Fig. 3D) over a 24 hour period. Cells 
treated with pro-HGF and 100 nM MCoTI-II displayed markedly less scattering (Fig. 3E), 
and scattering was completely abolished at 500 nM MCoTI-II (Fig. 3F). By contrast, MCoTI-
II had no effect on cell scattering induced by active HGF (Fig. 3C). Therefore, inhibition of 
matriptase by MCoTI-II on the surface of these cells restricts the bioavailability of active 
HGF and its downstream effects on cell scattering.  
 
MCoTI-II can inhibit matriptase activity in complex cellular processes: invasive cell 
migration 
In common with a variety of other proteolytic enzymes, matriptase is implicated in invasive 
cell migration (29), a process occurring subsequent to EMT in epithelial carcinogenesis. To 
determine whether MCoTI-II could inhibit this activity, we made use of two invasive prostate 
cancer cell lines that differ in their levels of matriptase expression. PC-3 cells display robust 
expression of matriptase, but it is essentially undetectable in DU-145 cells, as determined by 
qRT-PCR (13). Both cell lines were found to have similar rates of invasion through the 
basement membrane preparation, matrigel (Fig. 4). MCoTI-II inhibited the invasion of 
matriptase-expressing PC-3 cells by greater than 40%. However, MCoTI-II had no effect on 
the invasion of DU-145 cells, consistent with the lack of matriptase expression in these cells. 
 
MCoTI-II can inhibit matriptase activity in complex cellular processes: epithelial 
barrier formation  
Matriptase is known to play a role in epithelial barrier integrity in various tissues, and this can 
be recapitulated in cell culture (11). As we showed that MCoTI-II could inhibit matriptase 
activity in MDCK cells, we used these cells to study the role of matriptase in epithelial barrier 
formation and stability.  
MDCK cells grown on semi-permeable membranes develop functional tight junctions, 
which display trans-epithelial electrical resistance (TEER), a functional measure of tight 
junction integrity. MDCK-I cells develop high TEER over time (Fig. 5A), and this is reflected 
by the distribution of the canonical tight junctions proteins ZO-1 and claudin-1 (Fig. 5C). 
MCoTI-II was found to have only a minor effect on the acquisition of TEER in these cells. 
Concentrations up to 1 µM had no dose-dependent effect on the development of TEER up to a 
level of approximately 4000 Ω.cm2. Above this level, the TEER became slightly unstable and 
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the presence of MCoTI-II had a minor effect on its further development. Therefore, these 
observations suggest that in MDCK-I cells matriptase has only a minor role in the 
development of a functional epithelial barrier, or is poorly inhibited by MCoTI-II. 
Tight junctions are dynamic structures and can be readily disrupted by alteration of [Ca2+] 
in the medium, the so-called “calcium-switch” model (30). Removal of Ca2+ from the medium 
rapidly disrupts tight junction structure and function, assessed by loss of membrane 
localisation of ZO-1 and claudin-1 (Fig. 5D) and abolition of TEER (Fig. 5B), respectively. 
Repletion with Ca2+ leads to a slow reestablishment of TEER (Fig. 5B) and ZO-1 and claudin-
1 localisation (Fig. 5E). In contrast to the lack of effect of MCoTI-II on the initial 
establishment of functional tight junctions, the data in Fig. 5B show that MCoTI-II had a 
dramatic effect on the reestablishment of TEER. At a concentration of 250 nM, MCoTI-II 
caused at least a 5-fold prolongation of the rate of TEER development (determined as the time 
taken to reach the same level of TEER), rising to 10-fold at the highest concentration used. 
Therefore, in MDCK-I cells, matriptase activity is involved in the dynamic behaviour of tight 
junction and can be effectively inhibited by MCoTI-II.  
 
MCoTI-II does not inhibit matriptase-catalysed prostasin activation  
In addition to pro-HGF, the only other substrate for matriptase that has been demonstrated in 
vivo is the zymogen of the GPI-anchored serine protease prostasin (16). To determine whether 
MCoTI-II could inhibit this process, HEK293 cells which express neither of these proteases 
endogenously were transfected with both matriptase and prostasin. Cells transfected with 
prostasin alone displayed a single band of approximately 41 kDa on western blot 
corresponding to the inactive zymogen form of prostasin (Fig. 6). Co-transfection with 
matriptase led to complete activation of prostasin, with a single band observed at 38 kDa 
representing the C-terminal part of the protein after proteolytic activation at Arg-18. In 
contrast to the activation of pro-HGF, inclusion of MCoTI-II was unable to inhibit the 
matriptase-catalysed activation of pro-prostasin. In these experiments MCoTI-II was initially 
added 24 hours after transfection and incubated for a further 24 hours, without effect. 
Subsequently MCoTI-II was included directly after transfection of the cells, but inhibition of 
prostasin activation was still not observed (Fig. 6). 
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Discussion 
In the present study we have found that the cyclic cystine-knot microprotein MCoTI-II is 
an effective and specific inhibitor of the catalytic activity of the type-II transmembrane serine 
protease matriptase, influencing several biological functions that mirror the role of matriptase 
in vivo. Using a combination of biochemical and cell biological approaches we show that 
MCoTI-II efficiently inhibits the proteolytic activation of pro-HGF at the surface of 
matriptase-expressing cells, reducing the bioavailability of HGF and the induction of c-Met-
dependent cell-scattering. MCoTI-II was also found to inhibit the invasive migration of PC-3 
prostate carcinoma cells. In addition to these activities of matriptase that may underpin its 
involvement in cancer, MCoTI-II was also found to affect epithelial tight junction dynamics, 
potentially giving insights into the poorly understood role of matriptase in this process. 
Despite its efficacy, MCoTI-II was unable to inhibit the cellular activation of prostasin, a 
serine protease regarded as another major substrate for matriptase in vivo.  
Achieving specificity of inhibition and selectivity between enzymes with similar activities 
is one of the main challenges in the therapeutic use of inhibitors, and this is particularly true 
for proteolytic enzymes (31). In the cas  of matriptase, hepsin is a closely related protease that 
shares overlapping protein substrate specificity:.it can activate pro-HGF at the cell surface 
(13), and also activate both pro-uPA and pro-prostasin (19, 20). Therefore, the ability of 
MCoTI-II to discriminate between matriptase and hepsin, with a greater than 1000-fold 
differential in Ki values is an important feature of its inhibitory activity. The reason for this 
exceptional level of discrimination is not immediately clear, but matriptase and hepsin have 
significant differences in the loop regions surrounding the active site that are often responsible 
for modulating substrate accessibility (32). Matriptase has a large 60s insertion loop, which 
has been shown to engage in favourable electrostatic interactions with the Kunitz-type 
inhibitor BPTI, (33), and is modelled in proximity to Arg16-Arg17 of MCoTI-II (34). The 
equivalent loop in hepsin is 4-residues shorter and has a higher net positive charge, possibly 
disfavouring such interactions with MCoTI-II. The 90s-loop is also unusually large in hepsin 
which, based on the previous modelling with matriptase, may restrict access of MCoTI-II by 
sterically hindering the loop delimited by Cys21 and Cys25 of the inhibitor. Interestingly, 
although the inhibitory characteristics of MCoTI-II were determined using human matriptase, 
the experiments with MDCK cells demonstrate that it has a similar inhibitory potency against 
canine matriptase. This apparent lack of species specificity may prove to be useful, for 
example, in inhibiting matriptase activity in various animal models. 
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Our study confirms and extends the findings of a recent report demonstrating that MCoTI-
II is more potent than sunflower trypsin inhibitor (SFTI) as an inhibitor of matriptase in 
purified systems (34). This study also identified the variant MCoTI-II [V3R] (V7R in the 
numbering system used here) as having a 10-fold lower Ki value than the wild-type sequence. 
Several other macromolecular inhibitors have been shown to inhibit matriptase activity in 
purified systems, including variants of the natural protease inhibitors ecotin, eglin C and SFTI 
(35-38), although neither their efficacy in cellular systems nor their inhibitory activity towards 
hepsin have been reported. Irrespective of their affinity for matriptase, all of these inhibitors 
retain substantial inhibitory activity towards pancreatic trypsin, as also observed here for 
MCoTI-II. Whether this might contribute to potential biological effects of MCoTI-II (or other 
inhibitors of matriptase) via inhibition of non-pancreatic trypsin (mesotrypsin, PRSS3), which 
plays a role in several malignancies including prostate cancer, is not known, although this 
form of trypsin has been shown to be poorly inhibited by canonical trypsin inhibitors (39). 
Several small molecule inhibitors of matriptase have been developed, and some shown to 
be effective in vivo using xenograft models of tumour growth, albeit at high concentrations 
(40, 41). However, the inhibitory activity of these compounds against hepsin has not been 
reported, and our own data with the 3-amidinophenylalanine-based inhibitor CJ-730 (41) 
demonstrated a less than 5-fold selectivity between matriptase and hepsin,(13). Another 
disadvantage apparent with small molecule inhibitors is their efficacy in complex cellular 
systems is far lower than suggested by Ki values determined in solution. For example, an 
approximately 100-fold differential has been observed between the Ki values and the 
estimated IC50 values for the cellular activation of pro-HGF (13, 29), and 300-fold for the 
autoactivation of matriptase (42). This is in marked contrast to the efficacy of MCoTI-II in 
cellular systems, which demonstrates essentially complete inhibition of the cellular activities 
of matriptase at concentrations 10-20-fold above the Ki value; entirely consistent with full 
bioavailability of the inhibitor in these complex systems.  
Matriptase inhibition by MCoTI-II was found to inhibit the formaton of functional tight 
junctions in MDCK-I cells, using the Ca2+-switch model. This is in contrast to previous 
observations with overexpression of HAI-2, which was observed to increase the rate of 
acquisition of TEER in these cells (43). Although HAI-2 is clearly a major inhibitor of 
matriptase in vivo (43), it lacks selectivity, inhibiting a wide range of serine proteases in vitro 
(44), and, unlike MCoTI-II, inhibiting matriptase and hepsin equally well (18). Therefore, 
HAI-2 potentially inhibits a trypsin-like protease that acts to increase epithelial permeability, 
for example, by the degradation of junctional proteins (45, 46). Consistent with our 
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observations, siRNA silencing of matriptase in human Caco-2 epithelial cells has been shown 
to delay the reestablishment of TEER, as well as its initial acquisition (11, 47). The 
mechanism by which matriptase influences the behaviour of epithelial tight junctions is 
poorly understood, but appears to be independent of its established protein substrates (11).  
Despite the poor understanding of the role of matriptase in regulating epithelial barrier 
function, there is compelling evidencefor two authentic substrates in vivo, both of which have 
important roles in epithelial cell function. A mouse model of matriptase-initiated squamous 
cell carcinoma has been shown to be absolutely dependent on the presence of c-Met, directly 
implicating pro-HGF as a key substrate for matriptase (7). We demonstrate here that MCoTI-
II can effectively inhibit the activation of pro-HGF, both in MDCK and PC-3 cells, and that it 
was also able to inhibit the cell-scattering that is a central to the biological activity of HGF. 
The observation that MCoTI-II was able to inhibit the invasion of PC-3 cells suggests that 
matriptase can also promote carcinogenesis in an HGF-independent manner, possibly by 
direct effect on extracellular matrix proteins or by activation of the plasminogen activation 
system (15, 48). Members of the kallikrein-related family of serine proteases are thought to 
play significant roles in several of these process, but MCoTI-II was found to have no 
inhibitory activity towards either KLK2 (glandular kallikrein) or KLK3 (prostate-specific 
antigen), although neither of these proteases is highly expressed in PC-3 cells. 
The second substrate for matriptase demonstrated in vivo is the zymogen of the GPI-
anchored serine protease, prostasin (16). However, despite the efficacy of MCoTI-II, the 
activation of prostasin by matriptase was unaffected by MCoTI-II. This is potentially related 
to several unusual characteristics reported for this reaction. It has been suggested that 
prostasin activation is temporally coupled to matriptase activation (49) and that the latter can 
occur intracellularly (50) and, intriguingly, that prostasin can be activated by the zymogen 
form of matriptase (51). In either of these situations, the activation of prostasin might be 
expected to be refractory to inhibition by MCoTI-II. However, it cannot be completely 
excluded that our observation is related to limitations imposed by the extraordinary efficiency 
of prostasin activation, as we observe its complete activation when coexpressed with 
matriptase. However, inclusion of MCoTI-II for the duration of the experiment failed to affect 
prostasin activation; conditions where a steady-state level of the zymogen might be expected 
to accumulate.  
The specific and selective inhibition of matriptase activity by the macrocyclic cystine-knot 
microprotein MCoTI-II observed here in complex cellular systems demonstrates the potential 
usefulness of this type of inhibitor in the development of protease-targeted therapies. MCoTI-
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II has the ability to efficiently inhibit the activation of pro-HGF and HGF-dependent cell 
scattering, and invasive cell migration; processes closely linked to pathological events, 
particularly in cancer. Intriguingly, the lack of effect of MCoTI-II on prostasin activation may 
also be therapeutically beneficial, as the roles of matriptase in normal physiology are largely 
prostasin-dependent; highlighted be the similarity in the phenotypes of the respective null 
mice (16). In addition to its pro-carcinogenic roles, matriptase has been shown to have 
tumour-suppressive effects in colon carcinogenesis (52), consistent with its role in the 
maintenance of the epithelial barrier, as recapitulated here in MDCK-I cells. These opposing 
roles of matriptase in the initiation and progression of cancer highlight the importance of 
gaining a deeper understanding of the functions of matriptase in regulating epithelial cell 
behaviour for the development of potential therapeutic strategies. Highly specific matriptase 
inhibitors such as MCoTI-II and the MDCK cell model system described here may help 
contribute to this understanding. 
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FIGURE LEGENDS 
 
FIGURE 1. MCoTI-II specifically inhibits matriptase-catalysed activation of pro-HGF 
and pro-uPA. (A) Varying concentrations of MCoTI-II were incubated with either soluble 
matriptase (1 nM, left panel) or soluble hepsin (10 nM, right panel) and pro-HGF for 2 hours 
at 37° C. Activation of pro-HGF was determined by SDS-PAGE of reduced samples followed 
by western blotting for the C-terminal V5 epitope. (B) Varying concentrations of MCoTI-II 
were incubated with either soluble matriptase (1 nM, left panel) or soluble hepsin (10 nM, 
right panel) and pro-uPA for 1 hour at 37° C. Activation of pro-uPA was determined by SDS-
PAGE of reduced samples followed by western blotting for the C-terminal V5 epitope. (C) 
The generation of uPA activity  by either soluble matriptase (1 nM, left panel) or soluble 
hepsin (1 nM, right panel) was determined in the presence of varying concentrations of 
MCoTI-II (■ 0,  30, ∆ 100,  300, ◊ 1000 nM) and expressed as change in 
fluorescence/min for the hydrolysis of the uPA-specific substrate H-Glu-Gly-Arg-7-amino-4-
methylcoumarin. 
 
FIGURE 2. MCoTI-II inhibits the cellular activation of pro-HGF. MDCK-II or PC-3 cells 
were incubated with pro-HGF in the presence and absence of MCoTI-II (100 and 500 nM). 
Medium was removed at timed intervals, samples resolved by SDS-PAGE under reducing 
conditions and activation of pro-HGF determined by western blotting for the C-terminal V5 
epitope. Data shown are at 2 hours (left) and 4 hours (right) for PC-3 cells, and 4 hours 
incubation for MDCK-II cells. Control lanes are pro-HGF incubated in medium alone, and 
display a low molecular weight band due to traces of active, two-chain HGF as a minor 
contaminant in the purified protein preparation (13). 
 
FIGURE 3. Effect of inhibition of matriptase activity on HGF-induced cell scattering. 
MDCK cells were seeded at a density of 103 cells per well. Cells were treated with pro-HGF 
(10 ng/ml) in serum-free medium in the presence of 100 nM or 500 nM MCoTI-II for 24 
hours at 37° C. Cells treated with active HGF (10 ng/ml) and cells without HGF treatment 
served as positive and negative controls respectively. Cells were fixed with ice cold methanol 
for 5 minutes and images taken using the Zeiss CCD inverted microscope using a x10 
magnification. Data are representative of three separate experiments performed in duplicate. 
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FIGURE 4. Effect of MCoTI-II on cell invasion. Invasion of PC-3 and DU-145 cells 
through matrigel-coated semi-permeable membranes, in response to 2% FCS, was determined 
in the absence (solid bars) and presence of 100 and 500 nM MCoTI-II (open bars, 
concentrations indicated below) over a 24 hour time period. Data are shown as cell number 
invaded per microscopic field (mean +/- SEM). Statistical differences between inhibitor-
treated and untreated cells were assessed by Student’s t-test (* p<0.05). 
 
FIGURE 5. MCoTI-II abolishes the reestablishment of tight junctions in MDCK-I cells. 
(A) MDCK-I cells were grown on Transwell filters in the absence (•) or presence of varying 
concentrations of MCoTI-II ( 250 nM, ◊ 500 nM, ○ 1000 nM) and transepithelial electrical 
resistance (TEER) measured. (B) MDCK-I cells with high TEER were disrupted by removal 
of Ca2+ for 16 hrs (dashed line) prior to repletion with Ca2+. MCoTI-II concentrations as in 
panel A. In all experiments MCoTI-II was included at each change of culture medium. All 
TEER data shown are means of triplicate determinations. (C-E) Indirect immunofluorescence 
staining for tight junction proteins in MDCK-I cells grown on Transwell filters as for the 
TEER experiments. (C) Prior to Ca2+-switch, (D) after Ca2+-depletion, (E) after Ca2+-repletion 
for 24 hrs. Each panel shows claudin-1 staining (green), ZO-1 staining (red) and co-
localization (yellow). Loss of claudin-1 (green) and ZO-1 (red) localisation is apparent during 
the Ca2+-switch due to disruption of tight junctions, correlating with the changes in TEER 
shown in panel B.  
 
FIGURE 6. Effect of MCoTI-II on activation of prostasin zymogen. HEK-293 cells were 
transfected with either prostasin alone or cotransfected with both prostasin and matriptase. 
MCoTI-II (500 nM) was incubated with the cells 6 hours after transfection. Cell lysates were 
collected at 48 hours post-transfection and subjected to SDS-PAGE and western blot for 
prostasin. Prostasin zymogen is detected at 41 kDa in the cells transfected with prostasin 
alone, and the N-terminally truncated activated form is detected at 38 kDa in the cells 
cotransfected with matriptase. 
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What is known about this topic? 
• Matriptase is involved in a range of biological processes and these may be mediated by a 
range of protein substrates for this protease. 
• The closely related protease hepsin shares several different protein substrates with 
matriptase, yet has distinct biological functions. 
• Efforts to inhibit the proteolytic activity of matriptase are hampered by lack of 
specificity/selectivity of small molecule inhibitors. 
 
What does this paper add? 
• The cyclic microprotein MCoTI-II is identified as a high affinity inhibitor of matriptase 
that is highly selective with respect to inhibition of hepsin. 
• MCoTI-II efficiently inhibits the activity of matriptase against several of its known protein 
substrates in both purified and complex cellular systems. 
• MCoTI-II also inhibits the activity of matriptase that is required to maintain epithelial 
barrier function via an as yet unknown substrate. 
• The class of protease inhibitors exemplified by MCoTI-II have potential as highly selective 
inhibitors of matriptase in biological systems. 
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Table 1:Equilibrium dissociation constants (Ki) for MCoTI-II derivatives 
 
Protease 
Ki value (nM) 
MCoTI-II
a MCoTI-II 
[K10R] 
MCoTI-I MCoEeTI 
MCoEeTI 
[K10R] 
Matriptase 9.0 ± 1
b
 158 ± 46 155 ± 31 570 ± 85 370 ± 60 
Hepsin
c
 > 10
4 
> 10
4
 > 10
4 
> 10
4
 > 10
4
 
Trypsin 0.075 ± 0.005 0.085 ± 0.007 0.029 ± 0.002 48 ± 5 8.8 ± 0.3 
Chymotrypsin > 10
4
 > 10
4
 > 10
4
 ND
e 
ND 
Thrombin > 10
5
 > 10
5
 > 10
5
 ND ND 
uPA > 10
5
 > 10
5
 ND ND ND 
KLK2 > 10
4
 > 10
4
 ND ND ND 
KLK3 > 10
4
 > 10
4
 ND ND ND 
HLE
d 
> 10
5
 > 10
5
 > 10
5
 ND ND 
β-tryptase 600 ± 30 120 ± 50 1600 ± 140 33 ± 7 28 ± 2 
Subtilisin > 10
5
 > 10
5
 > 10
5
 ND ND 
 
(a) The amino acid sequences of these cyclic proteins, with P1 residue on bold and variations 
from the native MCoTI-II sequence underlined, are:  
MCoTI-II, SGSDGGVCPKILKKCRRDSDCPGACICRGNGYCG;  
MCoTI-II[K10R], SGSDGGVCPRILKKCRRDSDCPGACICRGNGYCG;  
MCoTI-I, SGSDGGVCPKILQRCRRDSDCPGACICRGNGYCG;  
MCoEeTI, SG----VCPKILKKCRRDSDCLAGCVCGPNGYCG;  
MCoEeTI[K10R],  SG----VCPRILKKCRRDSDCLAGCVCGPNGYCG. 
(b) Data are shown for soluble matriptase catalytic domain (expressed in E.coli), but Ki values 
were essentially unchanged using full-length soluble matriptase (expressed in Drosophila S2 
cells). 
(c) The maximum concentration of each inhibitor used was at least 2 µM, giving an estimated 
minimum Ki value of 10 µM in the absence of detectable inhibition. 
(d) Human leukocyte elastase 
(e) Not determined 
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FIGURE 1. MCoTI-II specifically inhibits matriptase-catalysed activation of pro-HGF and pro-uPA 
(A) Varying concentrations of MCoTI-II were incubated with either soluble matriptase (1 nM, left panel) or 
soluble hepsin (10 nM, right panel) and pro-HGF for 2 hours at 37° C. Activation of pro-HGF was determined 
by SDS-PAGE of reduced samples followed by western blotting for the C-terminal V5 epitope. (B) Varying 
concentrations of MCoTI-II were incubated with either soluble matriptase (1 nM, left panel) or soluble hepsin 
(10 nM, right panel) and pro-uPA for 1 hour at 37° C. Activation of pro-uPA was determined by SDS-PAGE of 
reduced samples followed by western blotting for the C-terminal V5 epitope. (C) The generation of uPA 
activity  by either soluble matriptase (1 nM, left panel) or soluble hepsin (1 nM, right panel) was determined 
in the presence of varying concentrations of MCoTI-II (■ 0, • 30, ∆ 100, ϒ 300, ◊ 1000 nM) and expressed 
as change in fluorescence/min for the hydrolysis of the uPA-specific substrate Glu-Gly-Arg-7-AMC.  
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FIGURE 2. MCoTI-II inhibits the cellular activation of pro-HGF. MDCK-II or PC-3 cells were incubated 
with pro-HGF in the presence and absence of MCoTI-II (100 and 500 nM). Medium was removed at timed 
intervals, samples resolved by SDS-PAGE under reducing conditions and activation of pro-HGF determined 
by western blotting for the C-terminal V5 epitope. Data shown are at 2 hours (left) and 4 hours (right) for 
PC-3 cells, and 4 hours incubation for MDCK-II cells. Control lanes are pro-HGF incubated in medium alone, 
and display a low molecular weight band due to traces of active, two-chain HGF as a minor contaminant in 
the purified protein preparation.  
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FIGURE 3. Effect of inhibition of matriptase activity on HGF-induced cell scattering. MDCK cells 
were seeded at a density of 103 cells per well. Cells were treated with pro-HGF (10 ng/ml) in serum-free 
medium in the presence of 100 nM or 500 nM MCoTI-II for 24 hours at 37°C. Cells treated with active HGF 
(10 ng/ml) and cells without HGF treatment served as positive and negative controls respectively. Cells were 
fixed with ice cold methanol for 5 minutes and images taken using the Zeiss CCD inverted microscope using 
a x10 magnification. Data are representative of three separate experiments performed in duplicate.  
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FIGURE 4. Effect of MCoTI-II on cell invasion. Invasion of PC-3 and DU-145 cells through matrigel-
coated semi-permeable membranes, in response to 2% FCS, was determined in the absence (solid bars) and 
presence of 100 and 500 nM MCoTI-II (open bars, concentrations indicated below) over a 24 hour time 
period. Data are shown as cell number invaded per microscopic field (mean +/- SEM). Statistical differences 
between inhibitor-treated and untreated cells were assessed by Student’s t-test (* p<0.05).  
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FIGURE 5. MCoTI-II abolishes the reestablishment of tight junctions in MDCK-I cells. (A) MDCK-I 
cells were grown on Transwell filters in the absence (•) or presence of varying concentrations of MCoTI-II ( 
250 nM, ◊ 500 nM, ○ 1000 nM) and transepithelial electrical resistance (TEER) measured. (B) MDCK-I cells 
with high TEER were disrupted by removal of Ca2+ for 16 hrs (dashed line) prior to repletion with Ca2+. 
MCoTI-II concentrations as in panel A. In all experiments MCoTI-II was included at each change of culture 
medium. All TEER data shown are means of triplicate determinations. (C-E) Indirect immunofluorescence 
staining for tight junction proteins in MDCK-I cells grown on Transwell filters as for the TEER experiments. 
(C) Prior to Ca2+-switch, (D) after Ca2+-depletion, (E) after Ca2+-repletion for 24 hrs. Each panel shows 
claudin-1 staining (green), ZO-1 staining (red) and co-localization (yellow). Loss of claudin-1 (green) and 
ZO-1 (red) localisation is apparent during the Ca2+-switch due to disruption of tight junctions, correlating 
with the changes in TEER shown in panel B.  
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FIGURE 6. Effect of MCoTI-II on activation of prostasin zymogen. HEK-293 cells were transfected 
with either prostasin alone or cotransfected with both prostasin and matriptase. MCoTI-II (500 nM) was 
incubated with the cells 6 hours after transfection. Cell lysates were collected at 48 hours post-transfection 
and subjected to SDS-PAGE and western blot for prostasin. Prostasin zymogen is detected at 41 kDa in the 
cells transfected with prostasin alone, and the N-terminally truncated activated form is detected at 38 kDa in 
the cells cotransfected with matriptase.  
48x25mm (600 x 600 DPI)  
 
 
Page 28 of 28Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
